Cocaine is a central nervous system stimulant derived from Erythroxylon coca.
Matthew Lambing, Eric Phillips, and Trisa Robarge, Thermo Fisher Scientific
Cocaine is a central nervous system stimulant derived from Erythroxylon coca. It is metabolized in-vivo resulting in the formation of ecgonine methyl ester, norcocaine, and benzoylecgonine. Cocaethylene is a substance formed when cocaine and ethanol are coadministered (1). A forensic toxicology method for the confirmation and quantitation of ecgonine methyl ester (EME), benzoylecgonine (BE), cocaine (COC), and cocaethylene (CE) in human urine was developed using the Thermo Scientific ISQ single quadrupole GC–MS system.
Each sample batch contained a matrix-matched single point calibrator (at 150 ng/mL), quality control samples set to contain each target compound at 40% and 125% of the calibrator (60 ng/mL and 187.5 ng/mL respectively), and a negative control (blank urine with internal standard only). Thermo Scientific HyperSep Verify-CX solid phase extraction columns were used for sample extraction. Samples were derivatized with hexafluoroisopropanol (HFIP) and pentafluoropropionic acid (PFPA or PFAA).
The ISQ™ mass spectrometer system was operated in selected ion monitoring mode, collecting 3 ions for each target compound, and 2 ions for each deuterated internal standard (Table I). A Thermo Scientific AS 3000 II autosampler and a Thermo Scientific TRACE GC Ultra gas chromatograph, equipped with a split/splitless injection port, provided sample introduction and separation. A 15 m x 0.25 mm i.d. x 0.25 µm film thickness Thermo Scientific TraceGOLD TG-5MS analytical column was used to enhance separation of the target cocaine class compounds from each other and from matrix components. Thermo Scientific ToxLab Forms software automated the acquisition and processing of all data, including quantitation and ion ratio confirmation calculations. For precision analyses, a coefficient of variation of <10% of the average calculated quality control amounts were required for each analyte, and inter-day percent differences of calculated amounts also had to be less than 10%.
Table I: Retention times and ions monitored for cocaine and metabolite analytes and their deuterated internal standards
A method was developed to demonstrate the performance of the ISQ GC–MS system for the confirmation and quantification of cocaine and its major metabolites in a urine matrix. The assay described offers broad linearity to cover a wide range of analyte concentrations, thus, reducing the need for dilutions or repeat extractions. Excellent precision was also demonstrated around the 150 ng/mL cutoff, with CV measurements of 10% or less over the study. Limits of detection and quantification at 15 ng/mL ensure sensitive performance for retest and directed assay samples. The methodology described offers a means for a forensic toxicology laboratory to confirm and quantify cocaine, benzoylecgonine, ecgonine methyl ester, and cocaethylene in human urine.
(1) Disposition of Toxic Drugs and Chemicals in Man, Eighth Edition. Randall C. Baselt, Biomedical Publications, 2008.
All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries.
Thermo Fisher Scientific
2215 Grand Avenue Parkway, Austin, TX 78728
tel. (800) 532-4752; fax (561) 688-8731
Website: www.thermoscientific.com
Using LC-MS/MS Analysis for PFAS Detection in Biological Samples and Serum
November 1st 2024Per- and polyfluoroalkyl substances (PFAS) are exceptionally versatile chemicals and have seemingly endless applications. Due to their persistent nature; prevalence in blood, food and environment; and emerging toxicity, there is a significant concern for their presence in the human body. Analysis is especially complicated due to background contamination in laboratory supplies and system. This paper will discuss sample preparation and LC-MS/MS analysis of an expanded panel of PFAS compounds in serum.
Robust Oligonucleotide Molecular Weight Confirmation via LC/MS
October 31st 2024Oligonucleotides—therapeutic agents for difficult-to-treat diseases—rely on precise molecular weight confirmation to ensure quality during development. Experts from Agilent Technologies explore the challenges of liquid chromatography-mass spectrometry (LC/MS) analysis in oligonucleotide synthesis, as well as strategies for accurate deconvolution, method development, and optimal equipment selection.